EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Liver X Receptor Inverse Agonist GAC0001E5 Impedes Glutaminolysis and Disrupts Redox Homeostasis in Breast Cancer Cells

Asitha Premaratne iD, Charles Ho iD, Shinjini Basu iD, Ashfia Fatima Khan, Tasneem Bawa-Khalfe, Chin-Yo Lin iD

Biomolecules · 2023

DOI: 10.3390/biom13020345 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Biomolecules, 2023. Verfasst von Asitha Premaratne und 5 weiteren Autor:innen. Beteiligte Einrichtung: Center for Nuclear Receptors and Cell Signaling, Department of Biology and Biochemistry, University of Houston, Houston, TX 77004, USA. Hauptthemen laut MEDLINE: Orphan Nuclear Receptors, Breast Neoplasms. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Golfers Against Cancer.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Liver X receptors (LXRs) are members of the nuclear receptor family of ligand-dependent transcription factors which regulate the expression of lipid and cholesterol metabolism genes. Moreover, LXRs and their ligands have been shown to inhibit tumor growth in a variety of cancers. We have previously identified the small molecule compound GAC0001E5 (1E5) as an LXR inverse agonist and a potent inhibitor of pancreatic cancer cells. Transcriptomic and metabolomic studies showed that 1E5 disrupts glutamine metabolism, an essential metabolic pathway commonly reprogrammed during malignant transformation, including in breast cancers. To determine the role of LXRs and potential application of 1E5 in breast cancer, we examined LXR expression in publicly available clinical samples, and found that LXR expression is elevated in breast tumors as compared to normal tissues. In luminal A, endocrine therapy-resistant, and triple-negative breast cancer cells, 1E5 exhibited LXR inverse agonist and “degrader” activity and strongly inhibited cell proliferation and colony formation. Treatments with 1E5 downregulated the transcription of key glutaminolysis genes, and, correspondingly, biochemical assays indicated that 1E5 lowered intracellular glutamate and glutathione levels and increased reactive oxygen species. These results indicate that novel LXR ligand 1E5 is an inhibitor of glutamine metabolism and redox homeostasis in breast cancers and suggest that modulating LXR activity and expression in tumor cells is a promising strategy for targeting metabolic reprogramming in breast cancer therapeutics.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Orphan Nuclear ReceptorsBreast NeoplasmsHumansFemaleLiver X ReceptorsLigandsDrug Inverse AgonismGlutamineHomeostasisOxidation-Reduction

Stichwörter der Autor:innen

breast cancerglutaminolysisligandsliver X receptormetabolism

Substanzen

Liver X ReceptorsOrphan Nuclear ReceptorsLigandsGlutamine

Autor:innen und Institutionen

  • Center for Nuclear Receptors and Cell Signaling, Department of Biology and Biochemistry, University of Houston, Houston, TX 77004, USA.

ORCID-Profile: Asitha Premaratne, Charles Ho, Shinjini Basu, Chin-Yo Lin

Förderung

  • Golfers Against Cancer

Zitieren

APA

Premaratne, A., Ho, C., Basu, S., Khan, A. F., Bawa-Khalfe, T., & Lin, C. Y. (2023). Liver X Receptor Inverse Agonist GAC0001E5 Impedes Glutaminolysis and Disrupts Redox Homeostasis in Breast Cancer Cells. Biomolecules. https://doi.org/10.3390/biom13020345

Vancouver

Premaratne A, Ho C, Basu S, Khan AF, Bawa-Khalfe T, Lin CY. Liver X Receptor Inverse Agonist GAC0001E5 Impedes Glutaminolysis and Disrupts Redox Homeostasis in Breast Cancer Cells. Biomolecules. 2023. doi:10.3390/biom13020345

BibTeX
@article{Premaratne2023,
  author = {Premaratne, Asitha and Ho, Charles and Basu, Shinjini and Khan, Ashfia Fatima and Bawa-Khalfe, Tasneem and Lin, Chin-Yo},
  title = {Liver X Receptor Inverse Agonist GAC0001E5 Impedes Glutaminolysis and Disrupts Redox Homeostasis in Breast Cancer Cells},
  journal = {Biomolecules},
  year = {2023},
  doi = {10.3390/biom13020345}
}
Kostenlos starten →